KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Other Accumulated Expenses (2018 - 2023)

Vir Biotechnology's Other Accumulated Expenses history spans 6 years, with the latest figure at $9.7 million for Q1 2023.

  • For Q1 2023, Other Accumulated Expenses fell 44.62% year-over-year to $9.7 million; the TTM value through Mar 2023 reached $9.7 million, down 44.62%, while the annual FY2022 figure was $12.7 million, 23.96% up from the prior year.
  • Other Accumulated Expenses for Q1 2023 was $9.7 million at Vir Biotechnology, down from $12.7 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $21.4 million in Q3 2022 and bottomed at $595000.0 in Q2 2020.
  • The 5-year median for Other Accumulated Expenses is $10.0 million (2021), against an average of $9.3 million.
  • The largest annual shift saw Other Accumulated Expenses plummeted 56.53% in 2019 before it surged 1173.79% in 2021.
  • A 5-year view of Other Accumulated Expenses shows it stood at $1.2 million in 2019, then crashed by 30.36% to $805000.0 in 2020, then soared by 1173.79% to $10.3 million in 2021, then increased by 23.96% to $12.7 million in 2022, then fell by 23.53% to $9.7 million in 2023.
  • Per Business Quant, the three most recent readings for VIR's Other Accumulated Expenses are $9.7 million (Q1 2023), $12.7 million (Q4 2022), and $21.4 million (Q3 2022).